CClinicalTrials.gg
CompletedNCT04091477NeuropsyTCAUpdated Mar 11, 2020

Impact of Neuropsychological Alteration of Patients With Eating Disorders

An observational study in Eating Disorder, sponsored by University Hospital, Montpellier. Completed at 1 site in France. Open to participants aged 15 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-03-11.

Sponsored by University Hospital, Montpellier · Observational

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
200
Ages
15 Years to 65 Years
Sex
All
01

Study summary

Eating disorders are multifactorial disorders currently conceptualized in a biopsychosocial model, but pathophysiology remains relatively unknown, and robust etiological models to guide treatment are therefore lacking. Different endophenotypes and neurocognitive vulnerability factors have been found in eating disorders including decision making abnormalities. The investigators hypothesize that decision making abnormalities are associated with a lower level of functioning and quality of life which could lead to social and interpersonal difficulties. The investigators also hypothesize that these anomalies are associated with a particular clinical profile (more restrictive profile, more hyperactivity, less insight on the disease and desire for care ...).

Read the detailed description

The investigators will recruit a total of 200 patients with an eating disorder in the university hospital of Montpellier.

Participation consists of a one-day visit with a multidisciplinary assessment. No action is specific to research. This is the usual management of patients with eating disorders addressed to our department.

02

Conditions studied

  • Eating Disorder

Keywords

  • Anorexia nervosa
  • Bulimia
  • Binge eating disorders
  • Neuropsychology
  • neurocognition
  • Daily functioning
03

In context

Feeding and Eating Disorders

740 studies on the registry are indexed under Feeding and Eating Disorders; 159 are open to participants now.

This study's enrollment of 200 is above the median of 100 across 183 observational studies indexed under Feeding and Eating Disorders.

Browse Feeding and Eating Disorders studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with eating disorder

Inclusion criteria

  • Patient with an eating disorder according to DSM-V criteria
  • Patient aged from 15 to 65 years
  • Patient who performs the day-hospital evaluation
  • Patient affiliated to a French social security system
  • Patient able to understand the nature, the aim and the methodology of the study For minor one of the legal guardians gave his consent

Exclusion criteria

Exclusion criteria:

  • Patient in an unstable somatic state (eg severe metabolic disorder making impossible or unreliable neuropsychological assessments)
  • Patient's refusal to participate
  • Patient protected by law (guardianship or curatorship)
  • Pregnant or nursing women. A dosage of βHCG will be performed to ensure the absence of pregnancy.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
200 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Level of functional impairment assessed by the clinician with the FAST scale

    We aim to investigate the link between global functioning and decision making abnormalities of patients with eating disorder. The Functioning Assessment Short Test (FAST) is composed of 24 items assessing various dimensions of daily functionning. Each item is ranged from 0 (no difficulty) to 3 (major difficulty) like a likert scale. The FAST is subdivided in 6 subscales : Autonomy (from 0 to 12), Professional activity (from 0 to 15), Cognitive functioning (from 0 to 15), Finances (from 0 to 6), interpersonal relationships (from 0 to 18) and Hobbies (from 0 to 6). The total score is the sum of the 6 subscales from 0 to 72. A hight score reveal hight difficulties in daily functionning

    Time frame: 1 day

Secondary outcomes

  1. Decision making assessed by the Iowa Gambling Task

    We aim to investigate the link between decision making abnormalities and eating disorder caracteristicus

    Time frame: 1 day

  2. Level of cognitive flexibility assessed by the Brixton test

    We aim to investigate the link between cognitive flexibility abnormalities and eating disorder caracteristicus

    Time frame: 1 day

  3. Level of central coherence assessed by the Rey Figure Test

    We aim to investigate the link between central coherence abnormalities and eating disorder caracteristicus

    Time frame: 1 day

07

Study locations

1 site
  • Uhmontpellier
    Montpellier, 34295, France
08

References and documents

Individual participant data

Plan to share: Undecided — NC

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04091477
Lead sponsor
University Hospital, Montpellier
Collaborators
INSERM 1061-Montpellier
Responsible party
Sponsor
First posted
Sep 16, 2019
Start date
Oct 1, 2019
Primary completion
Dec 1, 2019
Completion
Dec 30, 2019
Last update
Mar 11, 2020

Study contacts

Sébastien Guillaume, PhD
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion